AstraZeneca Plc and the University of Oxford, among the front-runners in the quest to deliver a Covid-19 vaccine, face mounting questions about their trial results after acknowledging a manufacturing error. While an announcement Monday by Astra and Oxford showed their shot was 70% effective on average in a late-stage study, the scant details released by the UK partners have sparked worries about whether regulators would clear it. In a later statement, Oxford said a difference in manufacturing processes led to some participants being given a half dose instead of a full one.
NDTV is one of the leaders in the production and broadcasting of un-biased and comprehensive news and entertainment programmes in India and abroad. NDTV delivers reliable information across all platforms: TV, Internet and Mobile.
Subscribe for more videos: https://www.youtube.com/user/ndtv?sub_confirmation=1
Like us on Facebook: https://www.facebook.com/ndtv
Follow us on Twitter: https://twitter.com/ndtv
Download the NDTV Apps: http://www.ndtv.com/page/apps
Watch more videos: http://www.ndtv.com/video?yt
NDTV is one of the leaders in the production and broadcasting of un-biased and comprehensive news and entertainment programmes in India and abroad. NDTV delivers reliable information across all platforms: TV, Internet and Mobile.
Subscribe for more videos: https://www.youtube.com/user/ndtv?sub_confirmation=1
Like us on Facebook: https://www.facebook.com/ndtv
Follow us on Twitter: https://twitter.com/ndtv
Download the NDTV Apps: http://www.ndtv.com/page/apps
Watch more videos: http://www.ndtv.com/video?yt
- Category
- Asia
- Tags
- NDTV 24x7, AstraZeneca, Oxford Vaccine
Sign in or sign up to post comments.
Be the first to comment